PORTFOLIO
PORTFOLIO COMPANIES
Violet Therapeutics, Inc.
-
- CEO：
- Meredith Fisher
COMPANY PROFILE
First-in-class platforms to identify, map and mine the cellular connectome at scale to elucidate novel drug targets
Violet is Drug discovery startup leveraging a first-in-class platforms, RABID-seq, to identify, map and mine the cellular connectome at scale, which was invented by Professor Francis Quintana at Brigham and Women’s Hospital and Harvard Medical School.
As its lead pipeline, Violet is developing a small molecule drug targeting novel candidates identified using RABID-seq, for neurodegenerative diseases.
As its lead pipeline, Violet is developing a small molecule drug targeting novel candidates identified using RABID-seq, for neurodegenerative diseases.
COMPANY STORY
Origin
Drug discovery startup leveraging a first-in-class platforms, RABID-seq, to identify, map and mine the cellular connectome at scale, which was invented by Professor Francis Quintana at Brigham and Women’s Hospital and Harvard Medical School
Strength
Intercellular interactions play a crucial role in the formation of diseases, but their molecular mechanisms have not been fully elucidated. Violet's RABID-seq technology enables comprehensive analysis of crosstalk between cells that are physiologically interacting, without depending on physical proximity. RABID-seq is expected to lead to the discovery of new drug target candidates, particularly in the field of neuroinflammation.
UTEC’s value add
Support for searching collaborative research partners to benefit pipeline development
-
scRNA-seq data lacks connectivity information
-
RABID-seq identifies targets in the context of in vivo connectome (Clark, Gutiérrez-Vázquez, Wheeler et al., 2021)
STORY LIST Interviews with leaders of UTEC's portfolio companies: past and present.